CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting treatment effectiveness.

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Food companies are capitalizing on the GLP-1 trend, offering high-protein, portion-controlled meals. But are they meeting ...

Jim Cramer, the host of Mad Money, discussed the upcoming market and corporate activity to look forward to this week, which ...

Some of the best health care stocks for February 2025, based on 30-day returns, include Akero Therapeutics Inc., Guardant Health Inc., and Inari Medical Inc. The best-performing health care stocks in ...

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...

Research tells us that eating enough protein and staying physically active can be helpful in reducing the amount of non-fat ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Wall Street is bullish on Viking, but the company still has a lot to prove. Viking has a number of different clinical studies ...

New research uncovers hidden risks and surprising benefits of weight loss drugs like Ozempic, reshaping how we see these ...